EIDX INVESTIGATION – Shareholder Rights Firm Labaton Sucharow is Investigating Eidos Therapeutics (NASDAQ: EIDX) for Potential Securities Violations and Breach of Fiduciary Duty
Labaton Sucharow, a prominent shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against Eidos Therapeutics (NASDAQ: EIDX). This investigation may affect current shareholders looking to protect their investments. The firm encourages Eidos shareholders to reach out to them for free information that could assist in safeguarding their holdings.
- Opportunity for shareholders to receive legal support and protect their investments.
- Ongoing investigation indicates potential legal risks for Eidos, which may affect stock performance.
NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ: EIDX).
If you currently own shares of Eidos and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll free number (800) 321-0476 or via email at dschwartz@labaton.com.
About the Firm
Labaton Sucharow LLP is one of the world’s leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at http://www.labaton.com.